4 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
Follow Alteogen, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer ALT-BB4, 0.9%NaCl - Health, Subjective | Phase 1 | Completed | Alteogen, Inc. | 290 | 2022-01-18 | 2026-01-29 |
| Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD Eylea, ALT-L9 - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Alteogen, Inc. | 28 | 2020-02-05 | 2022-01-20 |
| Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients ALT-P7 (HM2-MMAE) - HER2-positive Breast Cancer | Phase 1 | Completed | Alteogen, Inc. | 27 | 2018-01-11 | 2022-01-18 |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects ALT02, EU-licensed Herceptin, US-licensed Herceptin - Healthy | Phase 1 | Completed | Alteogen, Inc. | 105 | 2016-02-09 | 2017-08-21 |
Sodium Chloride (1) · aflibercept (1)
South Korea (3)